ClinicalTrials.gg

Program

AZD0240

A development code. Also written as “AZD0240: Autologous, engineered T Cells targeting KRAS G12D”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by AstraZeneca.

Furthest: phase 1, since Jan 9, 20241 company-led study, 1 open or runningNext primary completion: Aug 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 1since Jan 9, 2024Jan 9, 2024Aug 30, 2027phase 1 · NCT06218914
  • Named in AstraZeneca’s own pipeline as AZD0240, phase 1, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06218914 · 108 enrolled · United States

Ahead

  1. Aug 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06218914

TargetBeta

“AZD0240 targets KRAS G12D in the context of HLA-A\*11:01 or HLA-A\*11:02”study text, read by Claude · the study

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06218914Carcinoma, Non-Small-Cell Lung · United States1Active, not recruitingAug 30, 2027108

How it is read

Names in the registry

  • “AZD0240: Autologous, engineered T Cells targeting KRAS G12D”, 1 entry

Codes read as this program: AZD0240.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.